Announcing a new article publication for BIO Integration journal. In this mini review article the authors Meiyu Qiu and Pei Li from Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Republic of Korea summarize CRISPR/Cas-based Diagnostics and Gene Therapy.
Clustered regularly interspaced short palindromic repeats (CRISPR) technology, an easy, rapid, cost-effective, and precise gene-editing technique, has revolutionized diagnostics and gene therapy. Fast and accurate diagnosis of diseases is essential for point-of-care-testing (POCT) and specialized medical institutes. The CRISPR-associated (Cas) proteins system shed light on the new diagnostics methods at point-of-care (POC) owning to its advantages. In addition, CRISPR/Cas-based gene-editing technology has led to various breakthroughs in gene therapy. It has been employed in clinical trials for a variety of untreatable diseases, including cancer, blood disorders, and other syndromes. Currently, the clinical application of CRISPR/Cas has been mainly focused on ex vivo therapies.
Recently, tremendous efforts have been made in the development of ex vivo gene therapy based on CRISPR-Cas9. Despite these efforts, in vivo CRISPR/Cas gene therapy is only in its initial stage. In this review authors discuss milestones in CRISPR/Cas technologies that advance the field of diagnostics and gene therapy. Recent advances of diagnostics and gene therapy based on CRISPR/Cas technology are highlighted and the strength and significant challenges of the CRISPR/Cas technology for its future clinical usage in diagnosis and gene therapy are discussed.
Article reference: Meiyu Qiu and Pei Li, CRISPR/Cas-based Diagnostics and Gene Therapy. BIO Integration, 2021, https://doi.org/10.15212/bioi-2020-0048
BIO Integration is fully open access journal which will allow for the rapid dissemination of multidisciplinary views driving the progress of modern medicine.
As part of its mandate to help bring interesting work and knowledge from around the world to a wider audience, BIOI will actively support authors through open access publishing and through waiving author fees in its first years. Also, publication support for authors whose first language is not English will be offered in areas such as manuscript development, English language editing and artwork assistance.
###
BIOI is now open for submissions; articles can be submitted online at:
https://mc04.manuscriptcentral.com/bioi
Please visit http://www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
Please visit http://www.bio-integration.org to learn more about the journal.
Editorial Board: https://bio-integration.org/editorial-board/
BIOI is available on the IngentaConnect platform (https://www.ingentaconnect.com/content/cscript/bioi) and at the BIO Integration website (http://www.bio-integration.org).
Submissions may be made using ScholarOne (https://mc04.manuscriptcentral.com/bioi).
There are no author submission or article processing fees.
Follow BIOI on Twitter @JournalBio; Facebook (https://www.facebook.com/BIO-Integration-Journal-108140854107716/) and LinkedIn (https://www.linkedin.com/company/bio-integration-journal/).
ISSN 2712-0074
eISSN 2712-0082
Keywords: Clinical trials, CRISPR/Cas, diagnostics, gene therapy, point-of-care-testing.
Journal
BIO Integration